PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34203048-2 2021 Dipeptidyl peptidase-4 (DPP-4) is a therapeutic target for the management of T2DM, and its inhibitors prevent the degradation of glucose-dependent insulinotropic peptide and glucagon-like peptide 1, and thus, maintain their endogenous levels and lower blood glucose levels. Glucose 129-136 dipeptidyl peptidase 4 Homo sapiens 0-22 34203048-2 2021 Dipeptidyl peptidase-4 (DPP-4) is a therapeutic target for the management of T2DM, and its inhibitors prevent the degradation of glucose-dependent insulinotropic peptide and glucagon-like peptide 1, and thus, maintain their endogenous levels and lower blood glucose levels. Glucose 129-136 dipeptidyl peptidase 4 Homo sapiens 24-29 34203048-2 2021 Dipeptidyl peptidase-4 (DPP-4) is a therapeutic target for the management of T2DM, and its inhibitors prevent the degradation of glucose-dependent insulinotropic peptide and glucagon-like peptide 1, and thus, maintain their endogenous levels and lower blood glucose levels. Glucose 258-265 dipeptidyl peptidase 4 Homo sapiens 0-22 34203048-2 2021 Dipeptidyl peptidase-4 (DPP-4) is a therapeutic target for the management of T2DM, and its inhibitors prevent the degradation of glucose-dependent insulinotropic peptide and glucagon-like peptide 1, and thus, maintain their endogenous levels and lower blood glucose levels. Glucose 258-265 dipeptidyl peptidase 4 Homo sapiens 24-29